Certified by Founder Lodge
Eli Lilly and Company
United States - Indianapolis, Indiana
INVESTOR
1 Disclosed Funding Rounds $97,000,000
45 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
For more than a century, we have stayed true to a core set of values – excellence, integrity, and respect for people – that guide us in all we do: discovering medicines that meet real needs,
Company | Date | Round | Raised |
---|---|---|---|
Laverock Therapeutics | September, 28 ,2023 | Seed | $16,470,000 |
Amber Bio | August, 04 ,2023 | Seed | $26,000,000 |
Volastra Therapeutics | March, 08 ,2023 | Series A | $60,000,000 |
Sitryx | September, 28 ,2023 | Unknown | $39,500,000 |
Switch Therapeutics | March, 15 ,2023 | Series A | $52,000,000 |
Mariana Oncology | September, 08 ,2023 | Series B | $175,000,000 |
OrsoBio | November, 08 ,2023 | Series A | $60,000,000 |
Mediar Therapeutics | March, 15 ,2023 | Unknown | $105,000,000 |
Laverock Therapeutics | September, 28 ,2023 | Seed | $16,470,000 |
Vianautis | November, 14 ,2023 | Series A | $25,000,000 |
Therini Bio, Inc. | April, 27 ,2023 | Series A | $36,000,000 |
Sitryx | September, 28 ,2023 | Unknown | $39,500,000 |
Alto Neuroscience | November, 22 ,2023 | Series C | $45,000,000 |
DiogenX | May, 11 ,2023 | Series A | $30,056,125 |
OrsoBio | November, 08 ,2023 | Series A | $60,000,000 |
Capstan Therapeutics | March, 21 ,2024 | Series B | $175,000,000 |
Mozart Therapeutics, Inc | June, 08 ,2023 | Series A | $25,000,000 |
Vianautis | November, 14 ,2023 | Series A | $25,000,000 |
AltPep | June, 26 ,2023 | Series B | $53,000,000 |
Myricx Bio | July, 09 ,2024 | Series A | $115,246,800 |
Alto Neuroscience | November, 22 ,2023 | Series C | $45,000,000 |
Crossbow Therapeutics, Inc | July, 12 ,2023 | Series A | $80,000,000 |
Artax Biopharma Inc | August, 07 ,2024 | Unknown | $8,000,000 |
Capstan Therapeutics | March, 21 ,2024 | Series B | $175,000,000 |
Amber Bio | August, 04 ,2023 | Seed | $26,000,000 |
Arda Therapeutics | October, 10 ,2024 | Series A | $43,000,000 |
Myricx Bio | July, 09 ,2024 | Series A | $115,246,800 |
Mariana Oncology | September, 08 ,2023 | Series B | $175,000,000 |
TRexBio | November, 14 ,2024 | Series B | $84,000,000 |
Artax Biopharma Inc | August, 07 ,2024 | Unknown | $8,000,000 |
Laverock Therapeutics | September, 28 ,2023 | Seed | $16,470,000 |
Revisto | November, 19 ,2024 | Seed | $4,000,000 |
Arda Therapeutics | October, 10 ,2024 | Series A | $43,000,000 |
Sitryx | September, 28 ,2023 | Unknown | $39,500,000 |
TRexBio | November, 14 ,2024 | Series B | $84,000,000 |
OrsoBio | November, 08 ,2023 | Series A | $60,000,000 |
Revisto | November, 19 ,2024 | Seed | $4,000,000 |
Vianautis | November, 14 ,2023 | Series A | $25,000,000 |
Alto Neuroscience | November, 22 ,2023 | Series C | $45,000,000 |
Capstan Therapeutics | March, 21 ,2024 | Series B | $175,000,000 |
Myricx Bio | July, 09 ,2024 | Series A | $115,246,800 |
Artax Biopharma Inc | August, 07 ,2024 | Unknown | $8,000,000 |
Arda Therapeutics | October, 10 ,2024 | Series A | $43,000,000 |
TRexBio | November, 14 ,2024 | Series B | $84,000,000 |
Revisto | November, 19 ,2024 | Seed | $4,000,000 |